Page 7 - HFA_Dateline_2017_Q2_Summer
P. 7
Which brings us back to HR 2077. This legislation, like the bills of state regulation. This bill would safeguard patient health
we’ve advocated for at the state level, would establish impor- and return the power of practicing medicine back to the treat-
tant patient protections around the use of step therapy proto- ing physician by requiring health plans to grant exceptions
cols. As federal legislation, HR 2077 would govern the practices from step therapy protocols in appropriate circumstances:
of employer-sponsored health plans that are beyond the reach when the patient is stable on his/her current product, when the
step therapy product is not in the best interest of the patient
based on medical necessity, or when the patient has previously
tried the product.
HR 2077 offers vital protection to individuals with hemophilia
and other bleeding disorders who rely on prescription drug
therapy to treat their serious and chronic health conditions. For
these reasons, HFA will continue to work for passage of this
important piece of legislation. n n
Use your voice!
Contact your
Representatives to
encourage their support
of HR 2077, today!
Talk to your doctor to see if
ADYNOVATE may be right for you.
For more information, please visit
www.ADYNOVATE.com
©2016 Shire US Inc., Lexington, MA 02421. All rights reserved. 1-800-828-2088.
SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.
ADYNOVATE is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.
S32930 06/17
Fall 2017 | Dateline Federation 7
